STARTech Early Ventures

SensorLogic specializes in machine-to-machine (M2M) application hosting and offers a platform-as-a-service (PaaS) that delivers customizable M2M solutions integrated with a nationwide GSM/GPRS network. Through its XpressIQ Service Suite, SensorLogic provides customers with ready-to-use applications for GPS tracking, asset monitoring, and control, along with additional network services. By focusing on cloud-based M2M applications, SensorLogic enables businesses to efficiently manage and optimize their operations through advanced technology solutions.

SensorLogic specializes in machine-to-machine (M2M) application hosting and offers a platform-as-a-service (PaaS) that delivers customizable M2M solutions integrated with a nationwide GSM/GPRS network. Through its XpressIQ Service Suite, SensorLogic provides customers with ready-to-use applications for GPS tracking, asset monitoring, and control, along with additional network services. By focusing on cloud-based M2M applications, SensorLogic enables businesses to efficiently manage and optimize their operations through advanced technology solutions.

Mirage Networks was a network security company focused on providing effective and user-friendly security solutions for enterprises. The company specialized in network access control technology, offering a comprehensive platform that allowed users to manage network access across various devices, endpoints, and operating systems. Mirage operated through a global network of resellers, original equipment manufacturers, and managed security service providers, ensuring its solutions were widely accessible and easily integrated into existing systems.

QuickShift provides us with most of our warehousing and fulfillment services along with fleet support for distribution

Pintail Technologies, Inc. develops real-time adaptive test technology for semiconductor manufacturing companies. The company offers SwifTest, an on-line adaptive test modules that run directly on the automated test equipment (ATE), and capture and analyze data in real-time; and TestScape, an optional database system, which accepts data in real-time from SwifTest and supports various data management applications. Its solutions include TestScape-Charzilla that performs device characterization; TestScape-Aware, which provides a common dashboard for test results across multiple brands of testers and multiple test floors or subcons for issue identification and resolution; and TestScape-OPS that is used for on-line management of test floor and supports real-time overall equipment effectiveness (OEE) and life cycle management functions. The company's solutions also comprise TestVision, which is used to analyze test data and apply sophisticated statistical process control techniques to their test processes; SwifTest-TTO that performs real-time statistical sampling to achieve significant reductions in test time; and SwifTest-MAX, which offers the user a variety of user programmable triggers and alerts that are used to perform complex monitoring and binning analysis on-the-fly. It also provides professional services, such as test engineering, software customization, and training services. The company serves integrated device manufacturers, fabless, test and assembly, and automated test equipment manufacturing companies. It sells its products in the United States, Japan, Singapore, Malaysia, the Philippines, Taiwan, China, Korea, and Europe. Pintail Technologies has strategic alliances with Teradyne Inc. and Salland Engineering.

Reata Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for serious and life-threatening diseases by targeting key molecular pathways related to cellular metabolism and inflammation. The company is advancing several clinical trial programs, including Phase III trials for bardoxolone methyl, aimed at treating chronic kidney disease associated with Alport syndrome and pulmonary arterial hypertension linked to connective tissue disease. Additionally, omaveloxolone is undergoing Phase II trials for Friedreich’s ataxia, while other studies focus on various types of chronic kidney disease. Reata is also developing RTA 901 for neurological disorders and RORgT inhibitors for autoimmune and inflammatory diseases, currently in preclinical development. The company has strategic partnerships with Kyowa Kirin for the commercialization of bardoxolone in select Asian markets and with AbbVie for research and development of Nrf2 activators. Founded in 2002 and originally named Reata Discovery, Inc., the company is headquartered in Plano, Texas.

Voyence provides configuration and change management solutions that automate critical change, compliance, and activation processes. The company offers VoyenceControl NG solution, which manages various devices in a heterogeneous infrastructure; automates configuration management lifecycle, including design, change, and compliance; and collects data in its repository, including configuration, asset/hardware, and change and audit information. It offers compliance/security, change/configuration, and extending network management solutions. The company's customers include financial, healthcare, education, government, manufacturing, services, technology, and transportation organizations. Voyence, Inc. was founded in 2000 as PowerUp Networks and it changed its name to Voyence, Inc. in 2003. The company is headquartered in Richardson, Texas.

Metreos Corporation, founded in 2001 by Louis Marascio and Mark Richards, specializes in providing an IP telephony development and run-time platform that enables companies to build, deploy, and manage IP telephony applications. The company offers both packaged applications and a comprehensive set of tools for customizing and managing these applications within IP telephony networks. Metreos primarily serves large enterprises that have transitioned from traditional TDM phone systems to Voice-over-IP systems, particularly those utilizing Cisco Systems as their VoIP provider. Since 2004, notable clients such as Lehman Brothers and BearingPoint have utilized Metreos products to tailor their IP telephony solutions, compensating for features that were not carried over from their previous systems. In recognition of the value provided to its large enterprise customers, Cisco acquired Metreos in June 2006 for $28 million, further integrating its capabilities into Cisco's offerings.

AppTrigger, Inc. provides telecommunications application connectivity solutions. It offers Application Session Controller software, a network element that sits between the application cloud and the converging network/control layer to provide and manage connectivity to the evolving network for multiple applications. The company also provides support programs, and professional and training services. AppTrigger, Inc. was formerly known as Carrius Technologies, Inc. The company was founded in 2002 and is based in Richardson, Texas.

Metreos Corporation, founded in 2001 by Louis Marascio and Mark Richards, specializes in providing an IP telephony development and run-time platform that enables companies to build, deploy, and manage IP telephony applications. The company offers both packaged applications and a comprehensive set of tools for customizing and managing these applications within IP telephony networks. Metreos primarily serves large enterprises that have transitioned from traditional TDM phone systems to Voice-over-IP systems, particularly those utilizing Cisco Systems as their VoIP provider. Since 2004, notable clients such as Lehman Brothers and BearingPoint have utilized Metreos products to tailor their IP telephony solutions, compensating for features that were not carried over from their previous systems. In recognition of the value provided to its large enterprise customers, Cisco acquired Metreos in June 2006 for $28 million, further integrating its capabilities into Cisco's offerings.

AppTrigger, Inc. provides telecommunications application connectivity solutions. It offers Application Session Controller software, a network element that sits between the application cloud and the converging network/control layer to provide and manage connectivity to the evolving network for multiple applications. The company also provides support programs, and professional and training services. AppTrigger, Inc. was formerly known as Carrius Technologies, Inc. The company was founded in 2002 and is based in Richardson, Texas.

Reata Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for serious and life-threatening diseases by targeting key molecular pathways related to cellular metabolism and inflammation. The company is advancing several clinical trial programs, including Phase III trials for bardoxolone methyl, aimed at treating chronic kidney disease associated with Alport syndrome and pulmonary arterial hypertension linked to connective tissue disease. Additionally, omaveloxolone is undergoing Phase II trials for Friedreich’s ataxia, while other studies focus on various types of chronic kidney disease. Reata is also developing RTA 901 for neurological disorders and RORgT inhibitors for autoimmune and inflammatory diseases, currently in preclinical development. The company has strategic partnerships with Kyowa Kirin for the commercialization of bardoxolone in select Asian markets and with AbbVie for research and development of Nrf2 activators. Founded in 2002 and originally named Reata Discovery, Inc., the company is headquartered in Plano, Texas.

MacroGenics, Inc. is a biopharmaceutical company based in Rockville, Maryland, that specializes in the discovery and development of antibody-based therapeutics for cancer treatment. The company's pipeline includes several immuno-oncology candidates, such as Margetuximab, a monoclonal antibody currently in Phase III trials targeting HER2-expressing tumors, and Flotetuzumab, a DART molecule aimed at treating acute myeloid leukemia. Other investigational products include various monoclonal antibodies targeting immune checkpoints like PD-1 and B7-H3, as well as combination therapies that leverage multiple targets. MacroGenics employs advanced Fc engineering technology to enhance antibody functionality and is also exploring applications for autoimmune disorders and infectious diseases. The company has established strategic collaborations with several partners to advance its research and development efforts. Founded in 2000, MacroGenics is committed to innovating immunotherapeutics to address significant medical needs.

OraMetrix, Inc. provides 3-D technology solutions for facilitating and improving the quality of orthodontic care. It offers an orthodontic treatment system that allows the use of precision digital tools throughout the diagnosis, treatment planning and monitoring, and arch wire customization processes of the orthodontic treatment. OraMetrix, Inc. was formerly known as Orthotel, Inc. The company was founded in 1998 and is based in Richardson, Texas with an additional office in Berlin, Germany.